Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing amitriptyline hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing amitriptyline are listed in tablet form. No amitriptyline product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Amitriptyline is a tricyclic antidepressant that also acts on nerve pain pathways, commonly compounded in topical creams and gels and in oral liquids.
Amitriptyline is a tricyclic antidepressant. It blocks the reuptake of two brain signaling chemicals, norepinephrine and serotonin, and it also binds histamine, muscarinic, adrenergic and serotonin receptors and blocks voltage-gated sodium channels in nerves, which is why it has been studied for pain as well as mood. The manufactured product is amitriptyline hydrochloride tablets, FDA-approved for the relief of symptoms of depression. Amitriptyline is not approved for pediatric use.
A prescriber may order amitriptyline compounded when a patient needs a dosage form that is not manufactured, such as a topical preparation applied to a painful area or a liquid for someone who cannot swallow tablets, a strength that differs from the commercial tablets, a vehicle free of a specific dye or allergen, or a combination with other active ingredients. Compounded amitriptyline preparations are not FDA-approved and require a prescription.
The amitriptyline label carries a boxed warning: antidepressants increase the risk of suicidal thinking and behavior in children, adolescents and young adults, and anyone starting the medicine or changing a dose should be watched for new or worsening depression, agitation or unusual behavior changes. Do not use amitriptyline with a monoamine oxidase inhibitor (MAOI) or within 14 days of stopping one, with cisapride, during the acute recovery period after a heart attack, or if you are allergic to it. Other label warnings include heart rhythm problems, triggering mania in bipolar disorder, angle-closure glaucoma attacks, seizures, and withdrawal symptoms if stopped suddenly. It causes drowsiness and dry mouth, and alcohol and other sedating drugs add to this. Tell your prescriber or pharmacist if you take SSRIs, cimetidine, topiramate or any CYP2D6 inhibitor, because these can raise amitriptyline levels. The label advises use in pregnancy only if the potential benefit justifies the risk and states amitriptyline is excreted into breast milk; LactMed reports milk levels are low and adverse effects in breastfed infants would usually not be expected. If you notice a fast or irregular heartbeat, fainting, confusion or a severe rash, contact your prescriber or pharmacist right away.
Amitriptyline is a tertiary amine tricyclic antidepressant. It inhibits the norepinephrine and serotonin transporters with nanomolar affinity, has high affinity for histamine H1, muscarinic and 5-HT2A/2C receptors, binds adrenergic receptors, and produces state-dependent block of voltage-gated sodium channels via the local anesthetic receptor; NMDA receptor and potassium channel effects are also described. The label states the mechanism in humans is not known and that the drug is metabolized by N-demethylation and bridge hydroxylation. CYP2D6 poor metabolizers have higher than expected plasma concentrations, and CYP2D6 inhibitors may require lower doses. Systemic absorption from topical application is not characterized in the manufactured labeling.
Labeled indication: relief of symptoms of depression; not approved for pediatric patients or bipolar depression. Prescribers have ordered amitriptyline off label for postherpetic neuralgia, migraine prophylaxis and eating disorders (MedlinePlus), for fibromyalgia (Lawson, Biomedicines 2017), and as compounded topical amitriptyline for localized neuropathic pain, where trials of low-strength creams were negative and higher strengths showed systemic effects (Cline and Turrentine, Dermatitis 2016). Dosing and titration are per prescriber. Monitor for suicidality at initiation and dose changes, cardiac conduction in cardiovascular disease, anticholinergic burden in older adults, serotonin syndrome with serotonergic co-medication, and withdrawal on abrupt cessation. Amitriptyline is not a controlled substance.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
